Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Ophthotech Corporation Shares Tumbled 31% in January

By Todd Campbell - Feb 6, 2016 at 8:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The launch of trials in dry age-related macular degeneration failed to spark shares last month.

Source: Flickr user Luis Gustavo Zamudio A.

What: Despite kicking off new trials in dry age-related macular degeneration, shares in Ophthotech Corporation ( ISEE 2.21% ) dropped 31% in January, according to S&P Capital IQ.

So what: In January, Ophthotech Corporation initiated mid-stage clinical studies for Zimura, a novel drug that targets geographic atrophy, a common form of dry age-related macular degeneration (AMD). Globally, 8 million people suffer from vision loss tied to geographic atrophy, which happens when large areas of the retina stop functioning because of a buildup of yellow deposits called drusen. Currently, treatment options are limited and inadequate, consisting primarily of dietary changes.

Given the size and unmet need associated with the dry AMD market, Zimura expands Ophthotech's potential opportunity beyond its lead drug, Fovista, a therapy for the wet form of AMD. Wet AMD occurs when new blood vessels grow behind the retina and leak fluid into the retina, causing scarring.

Currently, Novartis' ( NVS 0.84% ) Lucentis, Regeneron's ( REGN 2.98% ) Eylea, and off-label use of Roche's ( RHHBY 1.83% ) Avastin are used to treat wet AMD in a market valued at $7.1 billion annually, and growing.

In phase 2 trials, combining Fovista with Lucentis boosted the number of letters patients could read on a standard eye chart by 62% versus Lucentis monotherapy, and additional trials could show a similar improvement in patient outcomes when Fovista is used alongside Eylea and Avastin.

Now what: Ophthotech has locked up Novartis as their ex-U.S. partner. Under that licensing pact, Ophthotech has already received $330 million of a potential total of $1 billion in upfront money and milestones. If phase 3 results that are expected in the fourth quarter of this year are good enough to support an approval, then Ophthotech will be paid royalties in excess of 30% on ex-U.S. sales.

As a result of the global population getting older, cases of AMD are becoming more common. Fovista's agnostic approach to current anti-VEGF therapies could turn it into a billion-dollar blockbuster.

Zimura's market potential could also be big, but Zimura trial results aren't likely to be available until 2018, so investors will need to be patient. 

Overall, since Fovista and Zimura could both be needle-moving drugs, investors may want to view the recent sell-off in Ophthotech's shares as a chance to add this company to portfolios. Obviously, there's a risk that Fovista and Zimura's trials fail; but if they don't, then owning shares could prove profit friendly.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
$50.68 (1.83%) $0.91
Novartis AG Stock Quote
Novartis AG
$81.36 (0.84%) $0.68
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$654.04 (2.98%) $18.95
IVERIC bio, Inc. Stock Quote
IVERIC bio, Inc.
$14.79 (2.21%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.